{"disease":{"id":"ctdna-monitoring","name":"ctdna monitoring"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06970912","title":"ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":393,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT07366112","title":"CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":158,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT05635630","title":"Predictive Value of ctDNA for NED Status in mCRC and Its Utility in Guiding Therapeutic Intervention","phase":"NA","overall_status":"UNKNOWN","enrollment_count":110,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT07292207","title":"Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Nagoya City University","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}